Background
Methods
Identification and data extraction of phase III studies
Identification, selection, and data extraction of early phase studies
Statistical analysis
Results
Identified phase III studies and their results
Study acronym/study title | Year of publication | Intervention | No. of subjects | Result |
---|---|---|---|---|
PAIS | 2009 | Acetaminophen | 1400 | Neutral |
AHAIS | 2001 | Aptiganel | 628 | Neutral |
BEST | 1988 | Atenolol, Propanolol | 302 | Neutral |
POST-010 and POST-011 | * | BMS-204352 | 1978 | Neutral |
SCAST | 2011 | Candesartan | 2004 | Neutral |
Cervene phase 3 | 2000 | Cervene (Nalmefene) | 368 | Neutral |
Citicoline ECCO 2000 | 2001 | Citicoline | 899 | Neutral |
Citicoline 007 | 1999 | Citicoline | 394 | Neutral |
ICTUS | 2012 | Citicoline | 2298 | Neutral |
CLASS | 1999 | Clomethiazole | 1360 | Neutral |
CLASS-I | 2002 | Clomethiazole | 1198 | Neutral |
EGASIS | 2006 | Diazepam | 880 | Neutral |
MACSI | 2013 | DP-b99 | 446 | Neutral |
EAIS | 1998 | Ebselen | 302 | Neutral |
EAST | 2009 | Edaravone | 814 | Neutral |
Eliprodil phase III | * | Eliprodil | 483 | Neutral |
EAST | 2001 | Enlimomab | 625 | negative |
ESS | 2009 | Epoetin Alfa | 522 | Neutral |
Fiblast phase III | 2002 | Fibroblast growth factor | 286 | Neutral |
FIST | 1996 | Flunarizine | 331 | Neutral |
Fosphenytoin phase III | * | Fosphenytoin | 462 | Neutral |
GAIN International | 2000 | Gavestinel (GV150526) | 1804 | Neutral |
GAIN Americas | 2001 | Gavestinel (GV150526) | 1367 | Neutral |
EST | 1994 | GM1 ganglioside | 792 | Neutral |
SASS | 1994 | GM1 ganglioside | 287 | Neutral |
IASSH | 1989 | GM1 ganglioside | 502 | Neutral |
ASCLEPIOS | 1994 | Israpidine | 357 | Neutral |
LUB-INT-13 | 2000 | Lubeluzole | 1786 | Neutral |
Lub | 1997 | Lubeluzole | 721 | Neutral |
IMAGES | 2004 | Magnesium | 2589 | Neutral |
PRISTINE | 1996 | Naftidrofuryl | 620 | Neutral |
ANS | 1992 | Nimodipine | 1064 | Neutral |
INWEST | 1994 | Nimodipine | 295 | negative |
TRUST | 1990 | Nimodipine | 1215 | Neutral |
VENUS | 2001 | Nimodipine | 454 | Neutral |
SAINT II | 2007 | NXY-059 | 3306 | Neutral |
SAINT I | 2006 | NXY-059 | 1722 | positive |
RREACT | 2007 | ONO-2506, Arundic acid | 841 | Neutral |
PASS | 1997 | Piracetam | 927 | Neutral |
mRECT | 2009 | Repinotan | 681 | Neutral |
ASSIST | 2000 | Selfotel (CGS19755) | 567 | Neutral |
RANTTAS | 1996 | Tirilazad mesylate | 556 | Neutral |
RANTTAS II | 1998 | Tirilazad mesylate | 126 | Neutral |
NEST-2 | 2009 | Transcranial laser therapy | 660 | Neutral |
ASTIN | 2003 | UK279,276 | 966 | Neutral |
ARTIST+ | * | YM872 | 312 | Neutral |
Early phase study characteristics and their association with phase III results
Study characteristics | All early phase studies (n = 59) | True neutral (n = 37) | False positive (n = 22) | aOR [95%-CI] | P |
---|---|---|---|---|---|
No. of subjects, median (IQR) | 92.0 (46.0-176.0) | 100.0 (46.0-157.0) | 91.5 (49.3-197.5) | 1.00 [0.99-1.00] | 0.713 |
Industry sponsored, n (%) | 36 (61.0) | 25 (67.6) | 11 (50.0) | 1.73 [0.40-7.54] | 0.465 |
Multicentered, n (%) | 41 (69.5) | 28 (75.7) | 13 (59.1) | 1.48 [0.28-7.87] | 0.643 |
Randomized, n (%) | 57 (96.6) | 35 (94.6) | 22 (100.0) | 0.00 [0.00-∞] | 1.000 |
Blinded outcome assessment, n (%) | 52 (88.1) | 34 (91.9) | 18 (81.8) | 3.95 [0.26-60.30] | 0.323 |
Dose–response investigated, n (%) | 16 (27.1) | 12 (32.4) | 4 (18.2) | 1.25 [0.26-6.07] | 0.786 |
Use of imaging endpoint, n (%) | 15 (25.4) | 8 (21.6) | 7 (31.8) | 0.46 [0.12-1.81] | 0.263 |
Duration of follow-up for endpoints*, median (IQR), days | 87.0 (30.0-90.0) | 90.0* (30.0-90.0) | 41.0 (28.0-90.0) | 1.00 [0.99-1.01] | 0.722 |
Same characteristics in phase I/II studies as in subsequent phase III studies | |||||
Same therapeutic time window, n (%) | 19 (32.2) | 10 (27.0) | 9 (40.9) | 0.69 [0.18-2.68] | 0.588 |
Same dose, n (%) | 29 (49.2) | 18 (48.6) | 11 (50.0) | 0.94 [0.28-3.14] | 0.916 |
Same route of administration, n (%) | 50 (84.7) | 34 (91.9) | 16 (72.7) | 3.33 [0.59-18.86] | 0.174 |